AG
TARS icon

Algert Global’s Tarsus Pharmaceuticals TARS Stock Holding History

Algert Global’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-31,760
Closed -$2.23M – 1407
2026
Q1 		$2.23M Sell
31,760
-14,225
-31% -$994K 0.03% 689
2025
Q4 		$3.77M Buy
+45,985
New +$3.43M 0.06% 536
2023
Q3 		– Sell
-47,152
Closed -$852K – 1251
2023
Q2 		$852K Buy
+47,152
New +$750K 0.04% 695

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Algert Global's TARS Position: Q2 2026 in Review

Algert Global sold out of Tarsus Pharmaceuticals (TARS) in Q2 2026, closing a stake of 31,760 shares — an estimated $2.23M sold.

Algert Global first reported a position in TARS in Q2 2023 and held it in 3 quarters. The position peaked at $3.77M in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Algert Global reported no remaining Tarsus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Algert Global sold 31,760 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $2.23M.
  • Algert Global first reported a position in Tarsus Pharmaceuticals in Q2 2023 and held it in 3 quarters.
  • Algert Global's Tarsus Pharmaceuticals position peaked at $3.77M in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.